Facebook Linkedin RSS Twitter Youtube
Home 2023

Janssen Pharmaceuticals

Beacon of Light: Retinal Gene Therapy Developer Launches with $120M
Drug Discovery

Beacon of Light: Retinal Gene Therapy Developer Launches with $120M

StockWatch: Moderna’s Positive Phase III RSV Vaccine Data Wows Analysts
Drug Discovery

StockWatch: Moderna’s Positive Phase III RSV Vaccine Data Wows Analysts

Ensuring the Purity of Gene Therapy Products and Vaccines
Drug Discovery

Ensuring the Purity of Gene Therapy Products and Vaccines

Jabbing at Alzheimer’s: AC Immune Takes Precision Approach to Vaccines
Drug Discovery

Jabbing at Alzheimer’s: AC Immune Takes Precision Approach to Vaccines

Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy
Drug Discovery

Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy

Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration
GEN Edge

Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration

HIV Vaccine Disappointment: Trial Data Show Lack of Sufficient Protection
Drug Discovery

HIV Vaccine Disappointment: Trial Data Show Lack of Sufficient Protection

J&J Seeks EUA for COVID-19 Vaccine
Coronavirus

J&J Seeks EUA for COVID-19 Vaccine

J&J Reports 66% Overall Efficacy for One-Dose COVID-19 Vaccine
Coronavirus

J&J Reports 66% Overall Efficacy for One-Dose COVID-19 Vaccine

J&J’s Janssen Pauses COVID-19 Vaccine Trials, Including 60,000-Patient Phase III Study
Coronavirus

J&J’s Janssen Pauses COVID-19 Vaccine Trials, Including 60,000-Patient Phase III Study

123...13Page 1 of 13
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.